Becker's Clinical Quality & Infection Control

November/December 2022 IC_CQ

Issue link: https://beckershealthcare.uberflip.com/i/1485806

Contents of this Issue

Navigation

Page 39 of 39

L E A D I N G W I T H O U T C O M E S "How can I reduce HAI rates with limited staff and cost constraints?" Nozin ® NOVA SM programs help hundreds of facilities reverse rising MRSA/MSSA HAI rates with minimal staff, low cost, even net savings. Our program outcomes show infection rate reductions at 53% to 100% with savings up to $1.4 million. 1 We provide tools, service and support. An assessment that includes a colonization risk profile for your facility is the first step. Start a free assessment at nozin.com/nova MRSA = methicillin-resistant Staphylococcus aureus, MSSA = methicillin-susceptible Staphylococcus aureus, HAI = Healthcare-Associated Infection. 1. References: nozin.com/clinical-outcomes. Outcomes reported by actual customers. Your results may vary. Nozin ® Nasal Sanitizer ® antiseptic is for nasal decolonization. ©2022 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin ® , Nasal Sanitizer ® , NOVA SM are trademarks of Global Life Technologies Corp. Nozin ® Nasal Sanitizer ® antiseptic is an OTC topical drug. No claim is made that it has an effect on any specific disease. Patent nos.: nozin.com/patents in Daily Patient Nasal Decolonization # 1 We can help.

Articles in this issue

Links on this page

view archives of Becker's Clinical Quality & Infection Control - November/December 2022 IC_CQ